La vendita allo scoperto per Abbott Laboratories dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Abbott Laboratories. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Abbott Laboratories (NYSE:ABT) Azioni, Report sulle vendite allo scoperto

ABBOTT LABORATORIES

Abbott Laboratories

Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Long Ideas

News

Markets

Media

Trading Ideas

CWST

SOFI

Jim Cramer su uno specifico titolo, con dettagli sulle ragioni dietro la sua valutazione e le implicazioni per gli investitori.

Jim Cramer lancia l&#39;allarme su questo titolo: ecco perché è preoccupato

Earnings

Pre-Market Outlook

IBKR

NFLX

Un&#39;analisi dei principali movimenti azionari che stanno catturando l&#39;attenzione degli investitori e delle aspettative per il futuro.

Netflix, Procter &amp; Gamble e altre 3 azioni da tenere d&#39;occhio oggi

Arcblock - United States Dollar

ALTEROLA BIOTECH INC by Alterola Biotech, Inc.

Alterola Biotech Inc

AB&T Financial Corp Com

Abits Group Inc

ABOITIZ EQTY VNT UNSP/ADR by Aboitiz Equity Ventures, Inc.

Aboitiz Equity Ventures Inc

Biotech

General

Abbott Laboratories Highlights Late-Breaking Data Of TriClip For People With Leaky Tricuspid Heart Valve

No one stumbles upon <a href="https://www.benzinga.com/personal-finance/24/12/42301100/most-americans-dont-see-wealth-as-the-key-to-financial-success-heres-what-matters-more-to-59-of-them">financial success</a> by accident. Wealth is built through discipline, learning from mistakes, and sticking to an approach even when the market seems to go awry. Few investing strategies showcase this better than <a href="https://www.benzinga.com/personal-finance/25/03/44374276/reddit-explodes-over-dividend-math-how-much-would-the-annual-dividend-be-for-a-280k-investment-investors-debate-schds-future-growth">dividend</a> investing.
Dividend investing is the slow-and-steady journey of the financial world, paying consistently while also providing growth in the background, making it perfect for retirees, long-term investors, and anyone who wants passive income.
Don't Miss:
<ul>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
</ul>
Still, this approach can also be risky for some if they pick the wrong stocks. One military veteran and Reddit user recently shared his investing journey that started with him making costly mistakes to now earning him $10,000 in dividends per year.
With 13 years of investing experience, the poster, an enlisted service member, had to learn what works through trial and error. He says he tried to be smarter than the market early on, leading to him selling big winners too soon and holding onto losers for too long.
&#8220;I bought [General Electric] in my Roth at what I thought was a great price point of $14.50 or something. Had to [dollar-cost average] over several years to bring the cost basis down and missed out on having that money in better spots in the biggest bull market year I have been a part of,&#8221; he shared.
The 36-year-old mentioned that he&#8217;s gradually shifted his strategy to dividend shares now and his $296,570 portfolio already generates over $10,000 annually in dividends. Let&#8217;s see what dividend shares and ETFs the investor holds.
Trending: BlackRock is calling 2025 the year of alternative assets. <a href="https://www.benzinga.com/money/masterworks">One firm from NYC has quietly built a group of 60,000+ investors who have all joined in on an alt asset class previously exclusive to billionaires like Bezos and Gates.</a>
<h2 class="wp-block-heading">From Fatal Mistakes to $10,000/Year in Dividend Income—Reddit Investor Shares Top 10 Stocks and ETFs in His Portfolio</h2>
Abbott Laboratories
Healthcare company, Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) specializes in medical devices, pharmaceuticals, and nutritional products. With a 1.89% dividend yield per year, ABT is known for its diversified product portfolio and steady payments.
AbbVie
Pharmaceutical giant AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) focuses on the research and development of therapies for various health conditions. Investors love ABBV because it has a strong yield, generating around 3.28% in dividends per year, and a stable pipeline of drugs.
ConocoPhillips
Energy giant ConocoPhillips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>) engages in the exploration and production of oil and natural gas. COP pays investors approximately 3.05% in annual dividends.
Duke Energy Corporation
Duke Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DUK#NYSE">DUK</a>) is one of the largest electric power companies in the U.S. and is known for its stable revenue and consistent dividends. DUK generates around 3.62% in annual dividend yield.
Apple
Technology giant Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) has a modest dividend yield but a strong growth potential, and that&#8217;s why both growth and income-focused investors are attracted to this stock. APPL pays investors around 0.47% in dividends per year.
See Also: Have $200K saved?<a href="https://www.benzinga.com/money/have-200k-saved-heres-how-to-turn-it-into-lasting-wealth"> Here's how to turn it into lasting wealth</a>
Mastercard
Electronic payments company Mastercard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) benefits from the ongoing shift toward cashless transactions. This, and the growth potential it offers makes MA a go-to stock for many investors. The company generates around 0.56% in annual dividends.
Verizon
Telecom Verizon Communications (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>) provides wireless and wireline services. With a dividend yield of approximately 6.25% annually, VZ has a stable cash flow, making it a favorite among individual stock investors.
Altria Group
Tobacco giant Altria Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MO#NYSE">MO</a>) is mainly known for the Marlboro brand. MO offers a high dividend yield of 7.21% per year, appealing to those seeking higher passive income.
Global X SuperDividend ETF
Tracking the performance of the Indxx SuperDividend U.S. Low Volatility Index, Global X SuperDividend ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIV#NYSE">DIV</a>) focuses on high dividend yields and is known to retain low volatility. DIV generates around 11.37% in dividend yield per year.
Invesco Preferred ETF
Invesco Preferred ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGX#NYSE">PGX</a>) invests mainly in preferred stocks, which are hybrid securities offering features of both stocks and bonds.​ Paying investors around 5.85% in annual dividends, PGX is a favorite for those who seek higher income.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
<li>Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a></li>
</ul>

Personal Finance

AAPL

ABBV

From Rookie Mistakes To $10K/Year In Dividends – Military Veteran Who 'Made A Few Great Plays' Shares His 10 Biggest Bets

Investors with a lot of money to spend have taken a bearish stance on Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ABT, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 9 uncommon options trades for Abbott Laboratories.
This isn't normal.
The overall sentiment of these big-money traders is split between 22% bullish and 77%, bearish.
Out of all of the special options we uncovered, 7 are puts, for a total amount of $659,000, and 2 are calls, for a total amount of $110,995.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $115.0 to $130.0 for Abbott Laboratories over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Abbott Laboratories's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Abbott Laboratories's significant trades, within a strike price range of $115.0 to $130.0, over the past month.
<h3>Abbott Laboratories Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742934628_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$9.05</td>
<td>$8.4</td>
<td>$8.5</td>
<td>$125.00</td>
<td>$357.0K</td>
<td>2.6K</td>
<td align="right">698</td>
</tr>
<tr>
<td>ABT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$8.55</td>
<td>$8.5</td>
<td>$8.55</td>
<td>$125.00</td>
<td>$74.3K</td>
<td>2.6K</td>
<td align="right">47</td>
</tr>
<tr>
<td>ABT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$2.61</td>
<td>$2.6</td>
<td>$2.61</td>
<td>$125.00</td>
<td>$72.5K</td>
<td>4.7K</td>
<td align="right">97</td>
</tr>
<tr>
<td>ABT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$8.7</td>
<td>$8.6</td>
<td>$8.63</td>
<td>$125.00</td>
<td>$61.1K</td>
<td>2.6K</td>
<td align="right">258</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$1.29</td>
<td>$1.28</td>
<td>$1.29</td>
<td>$129.00</td>
<td>$56.6K</td>
<td>21</td>
<td align="right">518</td>
</tr>
</tbody>
</table>

<h3>About Abbott Laboratories</h3>
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Having examined the options trading patterns of Abbott Laboratories, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of Abbott Laboratories</h3>
<ul>
<li>With a volume of 6,176,592, the price of ABT is down -1.27% at $125.6. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 22 days.</li>
</ul>
<h3>Expert Opinions on Abbott Laboratories</h3>
3 market experts have recently issued ratings for this stock, with a consensus target price of $154.67.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Citigroup has decided to maintain their Buy rating on Abbott Laboratories, which currently sits at a price target of $160. 
&#x2A; Consistent in their evaluation, an analyst from Goldman Sachs keeps a Buy rating on Abbott Laboratories with a target price of $154. 
&#x2A; Consistent in their evaluation, an analyst from B of A Securities keeps a Buy rating on Abbott Laboratories with a target price of $150. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Abbott Laboratories options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

Behind the Scenes of Abbott Laboratories's Latest Options Trends

Abbott Laboratories Announces That The FDA Has Approved An Investigational Device Exemption  For Its Coronary Intravascular Lithotrips  System To Evaluate The Treatment Of Severe Calcification In Coronary Arteries Prior To Stenting

Abbott Laboratories's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) short percent of float has risen 3.1% since its last report. The company recently reported that it has 22.93 million shares sold short, which is 1.33% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.93 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Abbott Laboratories Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742484625_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Abbott Laboratories has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Abbott Laboratories's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Abbott Laboratories's peer group average for short interest as a percentage of float is 4.23%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

What Does the Market Think About Abbott Laboratories?

Investors with a lot of money to spend have taken a bearish stance on Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ABT, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 10 uncommon options trades for Abbott Laboratories.
This isn't normal.
The overall sentiment of these big-money traders is split between 30% bullish and 60%, bearish.
Out of all of the special options we uncovered, 2 are puts, for a total amount of $305,520, and 8 are calls, for a total amount of $280,024.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $75.0 to $135.0 for Abbott Laboratories over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Abbott Laboratories's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Abbott Laboratories's substantial trades, within a strike price spectrum from $75.0 to $135.0 over the preceding 30 days.
<h3>Abbott Laboratories Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742313635_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$13.9</td>
<td>$13.4</td>
<td>$13.4</td>
<td>$130.00</td>
<td>$245.2K</td>
<td align="right">8</td>
<td align="right">228</td>
</tr>
<tr>
<td>ABT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$14.25</td>
<td>$13.4</td>
<td>$13.4</td>
<td>$130.00</td>
<td>$60.3K</td>
<td align="right">8</td>
<td align="right">45</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$5.75</td>
<td>$5.65</td>
<td>$5.65</td>
<td>$135.00</td>
<td>$47.4K</td>
<td align="right">456</td>
<td align="right">325</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$4.9</td>
<td>$4.85</td>
<td>$4.9</td>
<td>$135.00</td>
<td>$39.2K</td>
<td align="right">507</td>
<td align="right">174</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$4.85</td>
<td>$4.8</td>
<td>$4.8</td>
<td>$135.00</td>
<td>$36.9K</td>
<td align="right">507</td>
<td align="right">352</td>
</tr>
</tbody>
</table>

<h3>About Abbott Laboratories</h3>
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Having examined the options trading patterns of Abbott Laboratories, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of Abbott Laboratories</h3>
<ul>
<li>Trading volume stands at 2,698,821, with ABT's price down by -1.06%, positioned at $126.28.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 29 days.</li>
</ul>
<h3>Professional Analyst Ratings for Abbott Laboratories</h3>
3 market experts have recently issued ratings for this stock, with a consensus target price of $154.67.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Goldman Sachs has decided to maintain their Buy rating on Abbott Laboratories, which currently sits at a price target of $154. 
&#x2A; An analyst from Citigroup persists with their Buy rating on Abbott Laboratories, maintaining a target price of $160. 
&#x2A; An analyst from B of A Securities has decided to maintain their Buy rating on Abbott Laboratories, which currently sits at a price target of $150. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Abbott Laboratories with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Decoding Abbott Laboratories's Options Activity: What's the Big Picture?

B of A Securities analyst Travis Steed maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Buy and raises the price target from $133 to $150.

Price Target

Analyst Ratings

B of A Securities Maintains Buy on Abbott Laboratories, Raises Price Target to $150

Whales with a lot of money to spend have taken a noticeably bullish stance on Abbott Laboratories.
Looking at options history for Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) we detected 10 trades.
If we consider the specifics of each trade, it is accurate to state that 70% of the investors opened trades with bullish expectations and 20% with bearish.
From the overall spotted trades, 2 are puts, for a total amount of $101,085 and 8, calls, for a total amount of $453,044.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $120.0 to $150.0 for Abbott Laboratories over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Abbott Laboratories's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Abbott Laboratories's significant trades, within a strike price range of $120.0 to $150.0, over the past month.
<h3>Abbott Laboratories Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741625142_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$9.0</td>
<td>$8.85</td>
<td>$9.0</td>
<td>$140.00</td>
<td>$97.2K</td>
<td>400</td>
<td align="right">110</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$12.45</td>
<td>$12.0</td>
<td>$12.45</td>
<td>$140.00</td>
<td>$73.4K</td>
<td>2.0K</td>
<td align="right">10</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$10.75</td>
<td>$10.6</td>
<td>$10.75</td>
<td>$135.00</td>
<td>$64.4K</td>
<td>505</td>
<td align="right">125</td>
</tr>
<tr>
<td>ABT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/20/26</td>
<td>$5.05</td>
<td>$4.9</td>
<td>$5.05</td>
<td>$120.00</td>
<td>$57.0K</td>
<td>239</td>
<td align="right">113</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$12.85</td>
<td>$12.15</td>
<td>$12.45</td>
<td>$140.00</td>
<td>$56.0K</td>
<td>2.0K</td>
<td align="right">450</td>
</tr>
</tbody>
</table>

<h3>About Abbott Laboratories</h3>
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
In light of the recent options history for Abbott Laboratories, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is Abbott Laboratories Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 3,067,951, the ABT's price is up by 1.15%, now at $138.72. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 37 days.</li>
</ul>
<h3>What The Experts Say On Abbott Laboratories</h3>
2 market experts have recently issued ratings for this stock, with a consensus target price of $157.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Goldman Sachs keeps a Buy rating on Abbott Laboratories with a target price of $154. 
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Buy rating for Abbott Laboratories, targeting a price of $160. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Abbott Laboratories with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Abbott Laboratories Options Trading: A Deep Dive into Market Sentiment

March 6, 2025 records indicate that Senator Shelley M Capito filed a sale of Comcast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>), valued between $5,005 and $75,000. According to the March filing, the transaction occurred on March 6, 2025.
Currently, Comcast shares are trading up 1.12% at $36.67.
<h3>What Senator Has Been Trading Recently</h3>
Over the past three years, Shelley M Capito executed 117 trades totaling over $201 thousand. The largest of these trades were in Intel and Duke Energy stock. Some of the key transactions the Sen. has executed recently include: 
<ul>
<li>Comcast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>): $1,001 - $15,000 Sale</li>
<li>Accenture (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>): $1,001 - $15,000 Purchase</li>
<li>Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>): $1,001 - $15,000 Purchase</li>
</ul>
Here is a list of Shelley M Capito's most recent trades:
<table>
<thead>
<tr>
<th>Company</th>
<th>Ticker</th>
<th>Stock Type</th>
<th>Amount</th>
<th>Transaction Type</th>
<th>Transaction Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Meta Platforms Inc</td>
<td></td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>P</td>
<td>2025-02-25</td>
</tr>
<tr>
<td>Comcast</td>
<td>CMCSA</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>S</td>
<td>2025-02-24</td>
</tr>
<tr>
<td>Accenture</td>
<td>ACN</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>S (Partial)</td>
<td>2025-02-24</td>
</tr>
<tr>
<td>Abbott Laboratories</td>
<td>ABT</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>S (Partial)</td>
<td>2025-02-24</td>
</tr>
<tr>
<td>Apple</td>
<td>AAPL</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>S (Partial)</td>
<td>2025-02-05</td>
</tr>
</tbody>
</table>
To stay updated on Shelley M Capito's trades and other congressional trades, try our <a href="https://www.benzinga.com/gov-trades/members/shelley-m-capito">government trades tool</a> for live updates!
<h3>Why Congressional Transactions Matter</h3>
A congressional transaction is when any representative or senator either buys or sells an individual stock.
Anyone working in Congress must file a Periodic Transaction Report to inform the public of their recent transaction within 30 days of being notified of the transaction and within 45 days of the transaction date.
In April 2012, Former President Barack Obama signed the STOCK Act into law. The act prohibits members of Congress from using private information given to them by their position for personal gain such as buying or selling a stock. The act also expanded disclosure requirements for members of Congress by requiring them to file a monthly disclosure.
<h3>Why Congressional Transactions Matter</h3>
Congressional transactions shouldn't be the primary reason for an investing decision, but they can be an important factor for an investor to consider.
When a senator or representative makes a new purchase, it could be an indication they expect the stock to rise.
A sale, on the other hand, can be made for a variety of reasons, and may not necessarily mean the seller thinks the stock will go down.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Government

Politics

CMCSA

Recent Report Shows That Sen. Shelley M Capito Sold Up to $75K Worth of Comcast Stock

March 6, 2025 records indicate that Representative Jared Moskowitz filed a sale of West Pharmaceutical Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>), valued between $1,001 and $15,000. According to the March filing, the transaction occurred on March 6, 2025.
Currently, West Pharmaceutical Servs shares are trading down 0.0% at $232.76.
<h3>Representative's Recent Trading Activity</h3>
Over the previous three years, Jared Moskowitz conducted 293 trades, totaling more than $602 thousand. The largest of these were in Raymond James Finl and Seacoast Banking stock. Some of the most notable transactions the Rep. has executed recently include: 
<ul>
<li>Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>): $1,001 - $15,000 Sale</li>
<li>Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>): $1,001 - $15,000 Sale</li>
<li>Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>): $1,001 - $15,000 Sale</li>
</ul>
Here's a summary of Jared Moskowitz's most recent trades:
<table>
<thead>
<tr>
<th>Company</th>
<th>Ticker</th>
<th>Stock Type</th>
<th>Amount</th>
<th>Transaction Type</th>
<th>Transaction Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbott Laboratories</td>
<td>ABT</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>S</td>
<td>2025-01-15</td>
</tr>
<tr>
<td>Abbott Laboratories</td>
<td>ABT</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>S</td>
<td>2025-01-15</td>
</tr>
<tr>
<td>Abbott Laboratories</td>
<td>ABT</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>S</td>
<td>2025-01-15</td>
</tr>
<tr>
<td>AbbVie</td>
<td>ABBV</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>P</td>
<td>2025-01-15</td>
</tr>
<tr>
<td>AbbVie</td>
<td>ABBV</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>P</td>
<td>2025-01-15</td>
</tr>
</tbody>
</table>
Stay informed on Jared Moskowitz's trades and other members of Congress with our real-time <a href="https://www.benzinga.com/gov-trades/members/jared-moskowitz">government trades tracking tool</a>!
<h3>The Importance of Congressional Transactions</h3>
A congressional transaction is when any representative or senator either buys or sells an individual stock.
Anyone working in Congress must file a Periodic Transaction Report to inform the public of their recent transaction within 30 days of being notified of the transaction and within 45 days of the transaction date.
In April 2012, Former President Barack Obama signed the STOCK Act into law. The act prohibits members of Congress from using private information given to them by their position for personal gain such as buying or selling a stock. The act also expanded disclosure requirements for members of Congress by requiring them to file a monthly disclosure.
<h3>The Importance of Congressional Transactions</h3>
Congressional transactions shouldn't be the primary reason for an investing decision, but they can be an important factor for an investor to consider.
When a senator or representative makes a new purchase, it could be an indication they expect the stock to rise.
A sale, on the other hand, can be made for a variety of reasons, and may not necessarily mean the seller thinks the stock will go down.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Florida Rep. Jared Moskowitz Sold Up to $15K Worth of West Pharmaceutical Servs Stock

High-rolling investors have positioned themselves bullish on Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in ABT often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 11 options trades for Abbott Laboratories. This is not a typical pattern.
The sentiment among these major traders is split, with 72% bullish and 9% bearish. Among all the options we identified, there was one put, amounting to $41,820, and 10 calls, totaling $728,484.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $115.0 to $145.0 for Abbott Laboratories over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Abbott Laboratories's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Abbott Laboratories's substantial trades, within a strike price spectrum from $115.0 to $145.0 over the preceding 30 days.
<h3>Abbott Laboratories 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741284072_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$22.25</td>
<td>$21.95</td>
<td>$22.25</td>
<td>$115.00</td>
<td>$277.9K</td>
<td>1.2K</td>
<td align="right">127</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/14/25</td>
<td>$3.65</td>
<td>$3.05</td>
<td>$3.65</td>
<td>$132.00</td>
<td>$91.2K</td>
<td>202</td>
<td align="right">1</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$17.55</td>
<td>$16.45</td>
<td>$16.95</td>
<td>$120.00</td>
<td>$83.0K</td>
<td>533</td>
<td align="right">49</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$5.8</td>
<td>$5.75</td>
<td>$5.8</td>
<td>$145.00</td>
<td>$73.6K</td>
<td>321</td>
<td align="right">128</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$6.85</td>
<td>$6.7</td>
<td>$6.85</td>
<td>$135.00</td>
<td>$45.2K</td>
<td>1.1K</td>
<td align="right">235</td>
</tr>
</tbody>
</table>

<h3>About Abbott Laboratories</h3>
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
<h3>Abbott Laboratories's Current Market Status</h3>
<ul>
<li>With a trading volume of 4,532,529, the price of ABT is down by -2.37%, reaching $134.44.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 41 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Abbott Laboratories</h3>
In the last month, 2 experts released ratings on this stock with an average target price of $157.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Citigroup has decided to maintain their Buy rating on Abbott Laboratories, which currently sits at a price target of $160. 
&#x2A; Maintaining their stance, an analyst from Goldman Sachs continues to hold a Buy rating for Abbott Laboratories, targeting a price of $154. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Abbott Laboratories with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

During the last three months, 8 analysts shared their evaluations of Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), revealing diverse outlooks from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Abbott Laboratories and provided 12-month price targets. The average target is $145.12, accompanied by a high estimate of $160.00 and a low estimate of $135.00. This current average reflects an increase of 5.45% from the previous average price target of $137.62. 
<img src="https://www.benzinga.com/files/images/story/2025/1741114836_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Abbott Laboratories among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$160.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$154.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$158.00</td>
<td>$149.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$135.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Lawrence Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$136.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$135.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Danielle Antalffy</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$148.00</td>
<td>$146.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$135.00</td>
<td>$135.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Abbott Laboratories. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Abbott Laboratories compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Abbott Laboratories's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Abbott Laboratories's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ABT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Abbott Laboratories analyst ratings.</a>
<h2>All You Need to Know About Abbott Laboratories</h2>
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
<h3>Abbott Laboratories: A Financial Overview</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Abbott Laboratories's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 7.16%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Abbott Laboratories's net margin excels beyond industry benchmarks, reaching 84.1%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Abbott Laboratories's ROE excels beyond industry benchmarks, reaching 21.1%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Abbott Laboratories's ROA excels beyond industry benchmarks, reaching 11.85%. This signifies efficient management of assets and strong financial health.
Debt Management: Abbott Laboratories's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.32.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Abbott Laboratories Stands With Analysts

Citigroup analyst Joanne Wuensch maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Buy and raises the price target from $135 to $160.

Citigroup Maintains Buy on Abbott Laboratories, Raises Price Target to $160

Goldman Sachs analyst David Roman maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Buy and raises the price target from $138 to $154.

Goldman Sachs Maintains Buy on Abbott Laboratories, Raises Price Target to $154

<ul>
<li>Strengthens the Potential for Improved Patient Outcomes through Improvements in the Quality of Anticoagulation, Enhancing Hemocompatibility in HeartMate 3&#x2122; LVAD patients</li>
</ul>
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cadrenal.com%2F&amp;esheet=54218519&amp;newsitemid=20250304792377&amp;lan=en-US&amp;anchor=Cadrenal+Therapeutics&amp;index=1&amp;md5=849cf8be59121165ab208f7f5b1ad1c8">Cadrenal Therapeutics</a>, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVKD#NASDAQ">CVKD</a>), a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapeutics, with the late-stage asset tecarfarin, a new oral Vitamin K antagonist (VKA), today announced the signing of a Collaboration Agreement with Abbott (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) to support Cadrenal's pivotal TECarfarin Anticoagulation and Hemocompatibility with Left Ventricular Assist Devices (TECH-LVAD) trial.
Under the terms of the Collaboration and Data Sharing Agreement, Abbott will support Cadrenal on the planning and execution of the TECH-LVAD trial to evaluate the efficacy and safety of tecarfarin in patients with LVADs. Under the Agreement, Abbott will share insights from recent HeartMate 3&#x2122; trials and will support Cadrenal with: trial design, site identification, trial awareness, and HeartMate 3&#x2122; expertise.

CVKD

Cadrenal Therapeutics Announces Collaboration Agreement With Abbott In Support Of Pivotal Study Of Tecarfarin In Patients With HeartMate 3 LVAD

Abbott Laboratories's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) short percent of float has risen 21.7% since its last report. The company recently reported that it has 22.31 million shares sold short, which is 1.29% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.87 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Abbott Laboratories Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740762042_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Abbott Laboratories has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Abbott Laboratories's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Abbott Laboratories's peer group average for short interest as a percentage of float is 4.10%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

On Thursday, Dexcom, Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) fourth-quarter&nbsp;revenue rose 8% year-over-year to&nbsp;$1.114 billion,&nbsp;beating the analyst consensus <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">estimate of&nbsp;$1.104 billion</a>.
U.S. revenue rose by 4%, while international revenue rose by 17% on a reported basis and <a target="_blank" href="https://www.benzinga.com/25/02/43728537/dexcom-tops-sales-forecasts-as-international-growth-soars-19" rel="noreferrer noopener">19% on an organic basis</a>.
Outlook: Dexcom reaffirmed its FY25 guidance for revenue of $4.60 billion (vs. cons. of $4.61 billion), adjusted gross profit margin of around 64%–65%, and<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener"> adjusted operating margin of 21%</a>.
In December, Abbott Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) reached an agreement with DexCom to settle all outstanding patent disputes related to continuous glucose monitoring products.
The agreement <a target="_blank" href="https://abbott.mediaroom.com/Abbott-Agrees-to-Global-Continuous-Glucose-Monitoring-Litigation-Settlement-with-Dexcom" rel="noreferrer noopener">will</a> dismiss all pending cases in courts and patent offices worldwide. It also includes a provision that the parties will not litigate patent, trade dress, and design rights disputes with each other for the next 10 years. No financial payments are associated with the settlement from Abbott or Dexcom.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42274583/morgan-stanley-maintains-positive-medtech-outlook-despite-setbacks-in-2024-upgrades-intuitive-surgical-and-stryker-downgrades-nevro-and-glaukos" rel="noreferrer noopener">Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos</a>
Analyst Reactions: William Blair writes that DME's market share remained steady in Q4, and productivity has improved as planned, following a 40% commercial team expansion last year.
The analyst says the management expects further gains in productivity and another record year for new patient additions in 2025.&nbsp;&nbsp;
While the benefits of these improvements will take several quarters to materialize, especially as 2024 execution challenges fade in the second half, analyst Margaret Kaczor Andrew sees multiple growth drivers that could boost performance in 2025 and sustain revenue and earnings growth in the long term.
Andrew said that DexCom's challenges in 2024 may be temporary. She notes that DexCom is positioned for long-term growth, supported by its expanding product lineup, including G7, Dexcom One, and Stelo, and opportunities to reach new patient groups.
However, the analyst points out that DexCom's growth depends on adding new patients, particularly those with early-stage diabetes, with limited clinical data and reimbursement support.
Competition from major players like Medtronic Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) and Abbott Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) could also impact DexCom's expansion by capturing a share of new or existing patients in the continuous glucose monitoring market.
Morgan Stanley analyst Patrick Wood maintains DexCom with an Equal-Weight rating and raises the price <a target="_blank" href="https://www.benzinga.com/quote/DXCM/analyst-ratings" rel="noreferrer noopener">target from $75 to $82</a>.
Canaccord Genuity analyst William Plovanic maintains DexCom with a Buy and raises the price target from $99 to $103.
Price Action: DXCM stock is up 6.22% at $89.32 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43737281/pfizers-talzennaxtandi-combo-improves-survival-outcomes-in-metastatic-castration-resistant-prostate-cancer" target="_blank" rel="noreferrer noopener">Pfizer's Talzenna/Xtandi Combo Improves Survival Outcomes In Metastatic Castration-Resistant Prostate Cancer</a></li>
</ul>

Analyst Color

Large Cap

Guidance

Health Care

Movers

DXCM

Analyst Cautiously Optimistic On DexCom As Competitive Pressures Loom

February 11, 2025 records indicate that Representative Emily Randall filed a sale of Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), valued between $11,011 and $165,000. According to the February filing, the transaction occurred on February 11, 2025.
Currently, Abbott Laboratories shares are trading down 0.85% at $130.32.
Want to keep up with Emily Randall and other congressional members' stock activities? Check out our <a href="https://www.benzinga.com/gov-trades/members/emily-randall">government trades tool</a> for real-time updates!
<h3>The Importance of Congressional Transactions</h3>
A congressional transaction is when any representative or senator either buys or sells an individual stock.
Anyone working in Congress must file a Periodic Transaction Report to inform the public of their recent transaction within 30 days of being notified of the transaction and within 45 days of the transaction date.
In April 2012, Former President Barack Obama signed the STOCK Act into law. The act prohibits members of Congress from using private information given to them by their position for personal gain such as buying or selling a stock. The act also expanded disclosure requirements for members of Congress by requiring them to file a monthly disclosure.
<h3>Why Congressional Transactions Matter</h3>
Congressional transactions shouldn't be the primary reason for an investing decision, but they can be an important factor for an investor to consider.
When a senator or representative makes a new purchase, it could be an indication they expect the stock to rise.
A sale, on the other hand, can be made for a variety of reasons, and may not necessarily mean the seller thinks the stock will go down.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Rep. Emily Randall Has Sold Up to $165K Worth Of Abbott Laboratories Stock: Here's What You Should Know

Abbott Laboratories's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) short percent of float has risen 4.82% since its last report. The company recently reported that it has 14.97 million shares sold short, which is 0.87% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.07 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Abbott Laboratories Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739280759_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Abbott Laboratories has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Abbott Laboratories's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Abbott Laboratories's peer group average for short interest as a percentage of float is 3.78%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Abbott Laboratories's Recent Short Interest

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LXRX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$1.00</td>
<td>$168.9K</td>
<td>10.7K</td>
<td>17.1K</td>
</tr>
<tr>
<td>MDT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$93.00</td>
<td>$49.9K</td>
<td>25</td>
<td>604</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$130.00</td>
<td>$42.9K</td>
<td>6.5K</td>
<td>520</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$57.50</td>
<td>$53.5K</td>
<td>1.9K</td>
<td>112</td>
</tr>
<tr>
<td>AKRO</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$30.00</td>
<td>$102.8K</td>
<td>436</td>
<td>56</td>
</tr>
<tr>
<td>LNTH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$100.00</td>
<td>$45.0K</td>
<td>124</td>
<td>47</td>
</tr>
<tr>
<td>TMO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$650.00</td>
<td>$60.4K</td>
<td>70</td>
<td>30</td>
</tr>
<tr>
<td>REGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$720.00</td>
<td>$65.7K</td>
<td>6</td>
<td>25</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$540.00</td>
<td>$27.6K</td>
<td>625</td>
<td>21</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding LXRX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>), we observe a call option sweep with bearish sentiment. It expires in 24 day(s) on February 21, 2025. Parties traded 11262 contract(s) at a $1.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $168.9K, with a price of $15.0 per contract. There were 10734 open contracts at this strike prior to today, and today 17155 contract(s) were bought and sold. 
• For MDT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), we notice a call option sweep that happens to be bearish, expiring in 24 day(s) on February 21, 2025. This event was a transfer of 316 contract(s) at a $93.00 strike. This particular call needed to be split into 12 different trades to become filled. The total cost received by the writing party (or parties) was $49.9K, with a price of $158.0 per contract. There were 25 open contracts at this strike prior to today, and today 604 contract(s) were bought and sold. 
• Regarding ABT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), we observe a call option sweep with bearish sentiment. It expires in 24 day(s) on February 21, 2025. Parties traded 272 contract(s) at a $130.00 strike. This particular call needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $42.9K, with a price of $158.0 per contract. There were 6570 open contracts at this strike prior to today, and today 520 contract(s) were bought and sold. 
• Regarding CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we observe a call option sweep with bullish sentiment. It expires in 143 day(s) on June 20, 2025. Parties traded 100 contract(s) at a $57.50 strike. This particular call needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $53.5K, with a price of $535.0 per contract. There were 1923 open contracts at this strike prior to today, and today 112 contract(s) were bought and sold. 
• Regarding AKRO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKRO#NASDAQ">AKRO</a>), we observe a call option trade with neutral sentiment. It expires in 24 day(s) on February 21, 2025. Parties traded 46 contract(s) at a $30.00 strike. The total cost received by the writing party (or parties) was $102.8K, with a price of $2235.0 per contract. There were 436 open contracts at this strike prior to today, and today 56 contract(s) were bought and sold. 
• For LNTH (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>), we notice a call option sweep that happens to be bullish, expiring in 143 day(s) on June 20, 2025. This event was a transfer of 47 contract(s) at a $100.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $45.0K, with a price of $968.0 per contract. There were 124 open contracts at this strike prior to today, and today 47 contract(s) were bought and sold. 
• Regarding TMO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>), we observe a call option trade with bearish sentiment. It expires in 234 day(s) on September 19, 2025. Parties traded 30 contract(s) at a $650.00 strike. The total cost received by the writing party (or parties) was $60.4K, with a price of $2016.0 per contract. There were 70 open contracts at this strike prior to today, and today 30 contract(s) were bought and sold. 
• Regarding REGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>), we observe a call option trade with bullish sentiment. It expires in 52 day(s) on March 21, 2025. Parties traded 25 contract(s) at a $720.00 strike. The total cost received by the writing party (or parties) was $65.7K, with a price of $2630.0 per contract. There were 6 open contracts at this strike prior to today, and today 25 contract(s) were bought and sold. 
• For UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we notice a call option trade that happens to be bullish, expiring in 79 day(s) on April 17, 2025. This event was a transfer of 10 contract(s) at a $540.00 strike. The total cost received by the writing party (or parties) was $27.6K, with a price of $2760.0 per contract. There were 625 open contracts at this strike prior to today, and today 21 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKRO

LNTH

LXRX

REGN

9 Health Care Stocks With Whale Alerts In Today's Session

Press Releases

Abbott Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Financial Outlook

Abbott's 'Above the Bias' Film Reveals Misconceptions Can Impact Diabetes Care

Dividends

Abbott Declares 405th Consecutive Quarterly Dividend

Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD

Cagent Vascular Appoints Paul Wilson as Chief Commercial Officer to Drive Growth and Market Expansion

Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin

Abbott Initiates New Intravascular Lithotripsy Clinical Trial to Improve Outcomes in Patients with Coronary Artery Disease

Abbott Hosts Conference Call for First-Quarter Earnings

Abbott Receives CE Mark for its Volt™ Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms

New Late-Breaking Data Reinforce Benefits of Abbott's TriClip™ for People With Leaky Tricuspid Heart Valve

Baxter Intl

Becton, Dickinson and Company Common Stock

Becton Dickinson

Boston Scientific Corporation Common Stock

Boston Scientific

DexCom

Edwards Lifesciences Corporation Common Stock

Edwards Lifesciences

GE HealthCare Technologies Inc. - Common Stock

GE HealthCare Techs

Glaukos

Globus Medical, Inc. Class A Common Stock

Globus Medical

Hologic

IDEXX Laboratories

Inspire Medical Systems, Inc. Common Stock

Inspire Medical Systems

iRhythm Technologies, Inc. - Common Stock

iRhythm Technologies

Intuitive Surgical

Integer Holdings Corporation Common Stock

Integer Holdings

Masimo

Medtronic

Penumbra

Koninklijke Philips N.V. NY Registry Shares

Koninklijke Philips

Insulet

ResMed

Smith & Nephew

Steris

Stryker

Teleflex

Zimmer Biomet Holdings, Inc. Common Stock

Comments

Abbott Laboratories

Vendite allo scoperto

Abbott Laboratories (NYSE:ABT) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO